Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
5.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
6.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
7.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
8.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
; 17(6): e0269192, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653395
9.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
J Clin Oncol
; 40(8): 825-836, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757812
10.
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Eur Urol
; 82(1): 115-141, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35450732
11.
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Eur Urol
; 82(1): 6-11, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393158
12.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877084
13.
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Eur Urol
; 77(4): 508-547, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001144
14.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol
; 76(6): 719-728, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447077
15.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Eur Urol Oncol
; 1(6): 449-458, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31158087
16.
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
J Clin Oncol
; 35(14): 1530-1541, 2017 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28300506
17.
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
Eur Urol
; 82(1): e18-e19, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35440417
18.
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Eur Urol
; 66(5): 799-802, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24985962